Effect of raltegravir on the pharmacokinetics of methadone

Journal of Clinical Pharmacology

Volumn 50, Issue 12, 2010, Pages 1461-1466

  Anderson, Matt S ^a   Mabalot Luk, Julie Ann ^a   Hanley, William D ^a   Jin, Bo ^a   Riesenberg, Robert A ^b   Wenning, Larissa A ^a   Chodakewitz, Jeffery A ^a   Wagner, John A ^a   Iwamoto, Marian ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Atlanta Center for Medical Research   (United States)

Author keywords

HIV 1 integrase; interactions; methadone; pharmacokinetics; raltegravir

Indexed keywords

METHADONE; PLACEBO; RALTEGRAVIR;

ADULT; ARTICLE; BEDTIME DOSAGE; CAPSULE ENDOSCOPE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GEOMETRY; HUMAN; MAINTENANCE THERAPY; MALE; MORNING DOSAGE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT DURATION;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; HIV INTEGRASE INHIBITORS; HUMANS; ISOMERISM; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PYRROLIDINONES; YOUNG ADULT;

EID: 78649794167     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009360981     Document Type: Article

References (18)

1. Isentress [package insert]. Whitehouse Station, NJ: Merck & Co ; 2008.
2. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA. 1998 ; 280: 1936-1943.
3. Kassahun K., McIntosh I., Cui D., et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007 ; 35: 1657-1663.
4. Kharasch ED, Hoffer C., Whittington D., Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 ; 76: 250-269.
5. Eap CB, Buclin T., Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002 ; 41: 1153-1193.
6. Gourevitch MN, Friedland GH Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med. 2000 ; 67: 429-436.
7. Bruce RD, Altice FL, Gourevitch MN, Friedland GH Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006 ; 41: 563-572.
8. Iwamoto M., Kassahun K., Troyer MD, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008 ; 48: 209-214.
9. Wenning LA, Friedman EJ, Kost JT, et al. Lack of a significant drug interaction between raltegravir and tenofovir. Antimicrob Agents Chemother. 2008 ; 52: 3253-3258.
10. Iwamoto M., Wenning LA, Mistry GC, et al. Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clin Infect Dis. 2008 ; 47: 137-140.
11. Iwamoto M., Wenning LA, Petry AS, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008 ; 52: 4338-4343.
12. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr. 2007 ; B857: 15-19.
13. Garrido MJ, Troconiz IF Methadone: a review of its pharmacokinetic/ pharmacodynamic properties. J Pharmacol Toxicol Methods. 1999 ; 42: 61-66.
14. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000 ; 50: 427-440.
15. Wolff K., Sanderson M., Hay AW, Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem. 1991 ; 37: 205-209.
16. Hanley WD, Wenning LA, Moreau A., et al. Effect of tipranavirritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009 ; 53: 2752-2755.
17. Anderson MS, Kakuda TN, Hanley W., et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Antimicrob Agents Chemother. 2008 ; 52: 4228-4232.
18. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009 ; 53: 2852-2856.